found that CXCL9, CXCL10, CXCL11, and CCL5 were all highly expressed in metastatic melanoma patients, and this was associated with responsiveness to adoptive therapy and IL‐2 treatment 60. Here, CXCL9 is linked to metastatic melanoma.